Irritable bowel syndrome

BMJ (Online)

Volumn 345, Issue 7873, 2012, Pages

  Ford, Alexander C ^a,b   Talley, Nicholas J ^c  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; CIMETROPIUM; COLESEVELAM; DICYCLOVERINE; DISACCHARIDE; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; IBEROGAST; ISPAGULA; LINACLOTIDE; LUBIPROSTONE; MONOSACCHARIDE; OLIGOSACCHARIDE; OTILONIUM BROMIDE; PINAVERIUM; PLACEBO; PLANT EXTRACT; POLYOL; PROBIOTIC AGENT; PRUCALOPRIDE; RIFAXIMIN; SCOPOLAMINE; SEROTONIN UPTAKE INHIBITOR; STW 5; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ACUPUNCTURE; ANXIETY; BIFIDOBACTERIALES; BIPOLAR DISORDER; CHRONIC IDIOPATHIC CONSTIPATION; CHRONIC PAIN; COGNITIVE THERAPY; CONSTIPATION; DEPRESSION; DIAGNOSTIC TEST; DIET THERAPY; DRUG POTENCY; DYNAMIC PSYCOTHERAPY; EXERCISE; GASTROINTESTINAL SYMPTOM; GLUTEN FREE DIET; HERBAL MEDICINE; HUMAN; HYGIENE; HYPNOTHERAPY; INTESTINE FLORA; IRRITABLE COLON; ISCHEMIC COLITIS; LIFESTYLE MODIFICATION; PATHOPHYSIOLOGY; PATIENT EDUCATION; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SLEEP HYGIENE; UNSPECIFIED SIDE EFFECT; ADULT; ALTERNATIVE MEDICINE; FEMALE; MALE; MIDDLE AGED;

ADULT; COMPLEMENTARY THERAPIES; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PSYCHOTHERAPY;

EID: 84866085623     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e5836     Document Type: Review

References (30)

1. Lovell RM, Ford AC. Global prevalence of, and risk factors for, irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012;10:712-21.
2. Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol 2012;107:991-1000.
3. Ford AC, Talley NJ, Veldhuyzen Van Zanten SJ, Vakil NB, Simel DL, Moayyedi P. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? JAMA 2008;300:1793-1805.
4. Ford AC, Chey WD, Talley NJ, Malhotra A, Spiegel BMR, Moayyedi P. Yield of diagnostic tests for celiac disease in subjects with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch Intern Med 2009;169:651-8.
5. Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2011;10:CD003460.
6. Ford AC, Talley NJ, Spiegel BMR, Foxx-Orenstein AE, Schiller L, Quigley EMM, et al. Effect of fibre, antispasmodics, and peppermint oil in irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008;337:1388-92.
7. Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ, Knottnerus JA, Hoes AW. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ 2009;339:b3154.
8. Atkinson W, Sheldon TA, Shaath N, Whorwell PJ. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut 2004;53:1459-64.
9. Ong DK, Mitchell SB, Barrett JS, Shepherd SJ, Irving PM, Biesiekierski JR, et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol 2010;25:1366-73.
10. Biesiekierski JR, Newnham ED, Irving PM, Barrett JS, Haines M, Doecke JD, et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol 2011;106:508-14.
11. Johannesson E, Simren M, Strid H, Bajor A, Sadik R. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol 2011;106:915-22.
12. Saito YA, Prather CM, Van Dyke CT, Fett S, Zinsmeister AR, Locke III GR. Effects of multidisciplinary education on outcomes in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2004;2:576-84.
13. Lu WZ, Gwee KA, Moochhalla S, Ho KY. Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2005;15:927-34.
14. Ford AC, Moayyedi P. Meta-analysis: factors affecting placebo response rate in irritable bowel syndrome. Aliment Pharmacol Ther 2010;32:144-58.
15. Kaptchuk TJ, Friedlander E, Kelley JM, Sanchez MN, Kokkotou E, Singer JP, et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One 2010;5:e15591.
16. Ford AC, Talley NJ, Schoenfeld PS, Quigley EMM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009;58:367-78.
17. 4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2009;104:1831-43.
18. Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idipathic constipation: systematic review and meta-analysis. Gut 2011;60:209-18.
19. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364:22-32.
20. Moayyedi P, Ford AC, Brandt LJ, Foxx-Orenstein AE, Cremonini F, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010;59:325-32.
21. Zijdenbos IL, de Wit NJ, van der Heijden GJ, Rubin G, Quartero AO. Psychological treatments for the management of irritable bowel syndrome. Cochrane Database Syst Rev 2009;21:CD006442.
22. Lindfors P, Unge P, Arvidsson P, Nyhlin H, Bjornsson E, Abrahamsson H, et al. Effects of gut-directed hypnotherapy on IBS in different clinical settings-results from two randomized, controlled trials. Am J Gastroenterol 2012;107:276-85.
23. Gaylord SA, Palsson OS, Garland EL, Faurot KR, Coble RS, Mann JD, et al. Mindfulness training reduces the severity of irritable bowel syndrome in women: results of a randomized controlled trial. Am J Gastroenterol 2011;106:1678-88.
24. Manheimer E, Wieland LS, Cheng K, Li SM, Shen X, Berman BM, et al. Acupuncture for irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2012;107:835-47.
25. Saito YA, Rey E, Almazar-Elder AE, Harmsen WS, Zinsmeister AR, Locke GR, et al. A randomized, double-blind, placebo-controlled trial of St John's wort for treating irritable bowel syndrome. Am J Gastroenterol 2010;105:170-7.
26. Madisch A, Holtmann G, Plein K, Hotz J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther 2004;19:271-9.
27. Drossman DA, Chey WD, Johanson JF, Fass R, Scott C, Panas R, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome-results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009;29:329-41.
28. Chey WD, Lembo AJ, MacDougall JE, Lavins BJ, Schneier H, Johnston JM. Efficacy and safety of linaclotide administered orally for 26 weeks in patients with IBS-C: results from a randomized, double-blind, placebo-controlled phase 3 trial. Gastroenterology 2011;5(suppl 1):S135.
29. Money ME, Walkowiak J, Virgilio C, Talley NJ. Pilot study: a randomised, double blind, placebo controlled trial of pancrealipase for the treatment of postprandial irritable bowel syndrome-diarrhoea. Frontline Gastroenterol 2011;2:48-56.
30. Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, Burton D, Carlson P, Busciglio IA, et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol 2010;8:159-65.